2-(5-氟-3-吲哚基)-2-氧代乙酸乙酯 | 127561-11-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2-(5-氟-3-吲哚基)-2-氧代乙酸乙酯
• 英文名称: ethyl 2-(5-fluoro-1H-indol-3-yl)-2-oxoacetate
• 英文别名: ethyl 2-(5-fluoro-1H-indole-3-yl)-2-oxoacetate；(5-fluoro-1H-indol-3-yl)-oxo-acetic acid ethyl ester；5-fluoro-3-indoleglyoxylic acid ethyl ester；Ethyl 2-(5-Fluoro-3-indolyl)-2-oxoacetate
• CAS: 127561-11-9
• 化学式: C₁₂H₁₀FNO₃
• 分子量: 235.215
• InChiKey: JLGFKONPMDVGBH-UHFFFAOYSA-N

物化性质

• 沸点：
  395.0±22.0 °C(Predicted)
• 密度：
  1.350±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(5-氟-3-吲哚基)-2-氧代乙酸乙酯 在 LiAlH4 作用下， 以 四氢呋喃 为溶剂， 以100%的产率得到5-氟色醇
  参考文献：
  名称：

  1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines

  摘要：

  一些具有式I的1-吲哚基烷基-4-(烷氧基嘧啶基)哌嗪是有用的抗抑郁药物。取代基R.sup.1、R.sup.2和R.sup.5是氢或较低的烷基；R.sup.3和R.sup.4是氢、烷基、烷氧基、烷硫基、羧酰胺基、卤素或三氟甲基；R.sup.6是烷氧基；n是整数2或3。

  公开号：

  US05077293A1
• 作为产物：
  描述：

  5-氟吲哚 以 四氢呋喃 、 乙醚 、 乙醇 为溶剂， 生成 2-(5-氟-3-吲哚基)-2-氧代乙酸乙酯
  参考文献：
  名称：

  Structure-Based Design Leads to the Identification of Lithium Mimetics That Block Mania-like Effects in Rodents. Possible New GSK-3β Therapies for Bipolar Disorders

  摘要：

  More than two million American adults, or approximately one percent of the population 18 years or older, suffer from bipolar disorder. Current treatments include the so-called "mood stabilizers," lithium and valproic acid. Both are relatively dated drugs that are only partially effective and produce various undesirable side effects including weight gain. Based upon continued efforts to understand the molecular target for lithium, it now appears that specific inhibitors of the enzyme glycogen synthase kinase-3 beta (GSK-3 beta) may mimic the therapeutic action of mood stabilizers and might therefore allow for the design of improved drugs for treating patients with bipolar disorder as well as certain neurodegenerative disorders. Furthermore, the pro-apoptotic properties of the GSK-3 enzyme suggest the possible use of such inhibitors as neuroprotective agents. In fact, neuroprotection may contribute to the treatment of mood disorders. The present chemistry, modeling, and biology efforts have identified 3-benzofuranyl-4-indolylmaleimides as potent and relatively selective GSK-3 beta inhibitors. The best ligand in this series (having a K-i value of 4.6 nM against GSK-3 beta) was studied in a novel mouse model of mania that has recently been validated with several clinically effective mood stabilizers. This study presents the first demonstration of the efficacy of a GSK-3 beta inhibitor in this mouse model of mania. Selective brain penetrable GSK-3 ligands like those described herein become valuable research tools in better defining the role of this multifaceted kinase in both physiological and pathophysiological events.

  DOI：

  10.1021/ja068969w

文献信息

• [EN] 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT<br/>[FR] COMPOSÉS DE 3-(INDOLYL) OU 3-(AZAINDOLYL)-4-ARYLMALÉIMIDE ET LEUR UTILISATION DANS LE TRAITEMENT DES TUMEURS
  申请人：UNIV MAINZ JOHANNES GUTENBERG

  公开号：WO2011073092A1

  公开（公告）日：2011-06-23

  The present invention relates to a compound of formula (I) wherein R1, R2 and R3 are as defined in the description and the physiologically acceptable salts thereof as well as the physiologically acceptable solvates of the compounds of formula I and of the salts thereof. The compounds of formula I are suitable for treating tumors.

  本发明涉及一种化合物，其化学式为（I），其中R1、R2和R3如描述中所定义，并且其生理上可接受的盐以及化合物（I）及其盐的生理上可接受的溶剂。化合物（I）适用于治疗肿瘤。
• 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
  申请人：Bristol-Myers Squibb Company

  公开号：US04954502A1

  公开（公告）日：1990-09-04

  A series of 1,4-disubstituted piperazine derivatives comprised of indol-3-ylalkyl and substituted pyridin-2-yl substituent groups. These compounds are useful as antidepressant agents.

  一系列包含吲哚-3-基烷基和取代吡啶-2-基取代基团的1,4-二取代哌嗪衍生物。这些化合物可用作抗抑郁剂。
• Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor
  作者：Liyang Shi、Zhenpeng Zhong、Xitao Li、Yiqing Zhou、Zhengying Pan

  DOI：10.1021/acs.jmedchem.8b01823

  日期：2019.1.24

  pharmacokinetic properties. Thus, it may serve as a highly valuable tool molecule to study the overlapping roles of JAK family kinases in complex biological settings. Our study also suggested that for covalent kinase inhibitors, especially those targeting kinases with low Km ATP values, the reversible interactions between molecules and proteins should be carefully optimized to improve the overall potency.

  JAK家族激酶是免疫细胞信号传导的重要介体，Janus激酶3（JAK3）长期以来一直被视为自身免疫性疾病的潜在靶标。开发高选择性JAK3抑制剂的努力已经很多年了。但是，由于JAK3对5'-三磷酸腺苷（ATP）的强烈结合偏好，许多抑制剂在酶和细胞效能之间显示出较大的差距，这阻碍了剖析JAK3在细胞环境中的作用。使用靶向共价抑制剂方法，我们发现了化合物32，该化合物克服了酶促测定中的ATP竞争（1 mM），并证明了对小鼠CTLL-2和人外周血单核细胞中JAK3依赖性信号传导的抑制活性显着提高。化合物32在JAK家族中还显示出高选择性和良好的药代动力学特性。因此，它可能是一种非常有价值的工具分子，用于研究JAK家族激酶在复杂生物学环境中的重叠作用。我们的研究还表明，对于共价激酶抑制剂，尤其是那些针对具有低K m ATP值的激酶的抑制剂，应仔细优化分子与蛋白质之间的可逆相互作用，以提高整体效能。
• 3-(5-FLUOROINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT
  申请人：Johannes Gutenberg-Universität Mainz

  公开号：EP3187495A1

  公开（公告）日：2017-07-05

  The present invention relates to 3-(5-fluoroindolyl)-4-arylmaleimide compounds, pharmaceutical compositions containing them. The compounds of the present invention have antineoplastic activity. They can therefore be used for the treatment or prevention of tumors, in particular solid tumors.

  本发明涉及3-(5-氟吲哚基)-4-芳基马来酰亚胺化合物，含有这些化合物的药物组合物。本发明的化合物具有抗肿瘤活性。因此，它们可用于治疗或预防肿瘤，特别是固体肿瘤。
• 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
  申请人：Johannes Gutenberg-Universität Mainz

  公开号：EP2338486A1

  公开（公告）日：2011-06-29

  The present invention relates to the use of a compound of formula (I) wherein R1, and R3 are as defined in the description and R2 is a phenyl group which is substituted with 2 or 3 C1-G6 alkoxy groups, or a physiologically acceptable salt thereof, or a solvate of the compound of formula (I) or of the salt thereof, for treatment of colorectal or gastric adenocarcinoma.

  本发明涉及使用式(I)的化合物，其中R1和R3如描述中所定义，R2是带有2或3个C1-G6烷氧基取代的苯基，或其生理上可接受的盐，或式(I)的化合物或其盐的溶剂，用于治疗结肠或胃腺癌。